HIV patients may ditch daily pills for Twice-Yearly antibody shots
NCT ID NCT05275998
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 26 times
Summary
This study tested a combination of two lab-made antibodies (TMB-365 and TMB-380) in 51 adults with HIV whose virus was already well-controlled by daily oral medication. The goal was to see if these antibodies, given as intravenous infusions every 8 weeks, could safely keep the virus suppressed without needing daily pills. The study focused on safety, drug levels in the body, and whether the virus stayed undetectable for 24 weeks after stopping oral therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CAN Community Health
Fort Lauderdale, Florida, 33316, United States
-
Crofoot Research Center, Inc.
Houston, Texas, 77098, United States
-
Midway Immunology and Research Center
Ft. Pierce, Florida, 34892, United States
-
North Texas Infectious Disease Consultants
Dallas, Texas, 75246, United States
-
Orlando Immunology Center
Orlando, Florida, 32803, United States
-
Quest Clinical Research
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.